Cutaneous Lupus
Conditions
Brief summary
This multicenter study aims to evaluate treatment adherence and satisfaction of patients with cutaneous lupus, influenced by perception of the disease, fear of side effects, cost of medications and the doctor-patient relationship. Adherence will be measured by a VAS of 80% or higher on the Medical Adherence Self-Report Inventory scale.
Detailed description
This multicenter, cross-sectional study aims to characterize adherence to treatment and satisfaction of patients with cutaneous lupus. Non-adherence to treatment is a major problem, influenced by perception of the disease, fear of adverse effects, cost of medications and the doctor-patient relationship. Adherence will be measured by a VAS of 80% or more on the visual analog scale of the Medical Adherence Self-Report Inventory questionnaire. The study is descriptive, multicenter and cross-sectional. Participants will be adult patients suffering from cutaneous lupus, diagnosed by a dermatologist and under treatment, able to complete questionnaires. Patients with systemic lupus, cognitive or psychiatric disorders will be excluded from the study. The inclusion period is two years, with 30 minutes of follow-up per participant. The study will provide a better understanding of the feelings of patients with cutaneous lupus and the factors limiting their adherence to treatment.
Interventions
OTHERQuestionnaires
Responses to questionnaires: * Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) * Medical Adherence Self-Report Inventory (MASRI) * Morisky Medication Adherence Scale (MMAS4) * Visual analog scale (VAS) on the perception of disease control * Belief on Medicine Questionnaire (BMQ) * Care patient Feedback measure * Hospital Anxiety and Depression Scale (HAD) * Dermatology Life Quality Index (DLQI)
Sponsors
University Hospital, Toulouse
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with cutaneous lupus (pure cutaneous or subacute) diagnosed by a dermatologist and under local and/or systemic treatment for cutaneous lupus * No opposition to participation * Patient able to complete the questionnaires * Adult patient
Exclusion criteria
* Systemic lupus with multiple visceral involvement * Cognitive or psychiatric disorders preventing the smooth running of the study * Pregnant woman * Patient under guardianship/curatorship or safeguard of justice
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of adherence to treatment of patients with cutaneous lupus. | Inclusion day | Adherence is defined by a VAS greater than or equal to 80% on the Visual Analog Scale of the MASRI (Medical Adherence Self-Report Inventory) questionnaire. |
Countries
France
Contacts
PRINCIPAL_INVESTIGATORCarle PAUL, MD
University Hospital, Toulouse
Outcome results
None listed